We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preliminary results of propranolol treatment for patients with infantile hemangioma.
- Authors
Çprapcioğlu, Funda; Büyükkapu-Bay, Sema; Binnetoğlu, Köksal; Babaoğlu, Abdulkadir; Tugay, Melih; Anık, Yonca
- Abstract
Propranolol, a non-selective β-blocker, has recently been introduced as a treatment for infantile hemangiomas. In this study, we evaluated the effect of propranolol in 12 infants with hemangloma. Twelve infants (9 girls) with a median age of 4.5 months were included in the study. All of the patients in the study group received short-term (1-9 weeks, median: 4 weeks) systemic corticosteroids as a first-line therapy. All patients received propranolol 2 mgikg/day, divided into three doses. They were treated in an inpatient setting for the first 72 hours of the treatment. Vital signs, blood pressure and blood glucose were monitored. Propranolol treatment was given for 4-9 months (median: 5 months). In the study group, regression rate of the mean dimension of the lesion was 38%±15 (range 15% 50, median 45%) at the 2nd month of therapy. Over 9 months, which was the maximum follow-up period, the regression rate of the mean dimension of the lesion was 55%±31 (range 20%-80, median 50%). One patient had transient bradycardia, which improved spontaneously. No other side effect was observed in the study population. Propranolol appears to be an effective drug for infantile hemangiomas with good clinical tolerance. We suggest that propranolol is the preferable drug as the first-line therapy for infantile hemangiomas.
- Subjects
HEMANGIOMAS; PROPRANOLOL; INFANT diseases; BLOOD pressure; SYMPTOMS; DRUG efficacy; REGRESSION analysis; FOLLOW-up studies (Medicine); THERAPEUTICS
- Publication
Turkish Journal of Pediatrics, 2011, Vol 53, Issue 2, p137
- ISSN
0041-4301
- Publication type
Article